Chemical Reprogramming of Glial Cells into Neurons
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for regenerating functional neurons in neurodegenerative disorders or after nerve injury face challenges such as immunorejection, tumorigenesis, and the need for viral infection and sophisticated surgery, making them unsafe and inefficient.
Innovation Solution
Chemical reprogramming of glial cells into neurons using small molecules like thiazovivin, LDN193189, SB431542, CHIR99021, DAPT, VPA, and purmorphamine, which inhibit specific signaling pathways to convert astrocytes, NG2 glia, or microglia into functional neurons without introducing exogenous genes or cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell replacement therapy using exogenous cells is used to regenerate functional neurons, then neuronal regeneration is achieved, but immunorejection and tumorigenesis risks occur
Solution Approach 1:
The patent utilizes the body's own glial cells as the source of neuronal regeneration, eliminating the need for exogenous cell transplantation. The small molecules trigger endogenous glial cells to convert into functional neurons, thereby avoiding immunorejection and tumorigenesis risks associated with external cell sources while achieving reliable neuronal regeneration
2Reliability
If viral infection methods are used to convert astroglial cells into neurons, then neuronal conversion is achieved, but surgical complexity and safety risks increase
Solution Approach 1:
The patent replaces the mechanical and surgical intervention of viral injection methods with a chemical approach using small molecules. Instead of requiring intracranial injection of viral particles and sophisticated brain surgery, the small molecules are administered to trigger glial cell conversion, thereby achieving neuronal conversion while eliminating surgical complexity and associated safety risks
3Reliability
If stem cell manipulation is used to differentiate into neurons, then neuronal generation is achieved, but process complexity and time requirements increase
Solution Approach 1:
The patent employs small molecules that directly trigger glial cells to convert into functional neurons without requiring lengthy differentiation processes. The small molecules are designed to activate specific signaling pathways that lead to rapid neuronal conversion, thereby achieving reliable neuronal generation while significantly reducing the time loss associated with traditional stem cell manipulation and differentiation protocols
Data Source
AI summary
Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-β), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and γ-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG; purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.